Keay Nakae
Stock Analyst at Chardan Capital
(4.11)
# 515
Out of 5,182 analysts
243
Total ratings
41.04%
Success rate
17.86%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $30 | $24.52 | +22.35% | 4 | Apr 22, 2026 | |
| PRQR ProQR Therapeutics | Maintains: Buy | $4 | $1.55 | +158.06% | 17 | Apr 9, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $1.68 | +197.62% | 8 | Apr 9, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $53.20 | +87.97% | 8 | Mar 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $425 | $305.54 | +39.10% | 16 | Mar 25, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 | $34.03 | +2.85% | 2 | Mar 18, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.32 | +224.07% | 24 | Mar 16, 2026 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.13 | +384.26% | 14 | Mar 12, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 → $14 | $3.52 | +297.73% | 20 | Mar 11, 2026 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $18.26 | +108.11% | 16 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $15 | $12.89 | +16.37% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $73.91 | +8.24% | 23 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 | $0.90 | +4,342.47% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.20 | +19.05% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $7.70 | +354.55% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $8.10 | -25.93% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.97 | +204.57% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.41 | +1,865.60% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $15.52 | -61.34% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $1.11 | +34,134.23% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.03 | +584.93% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $3.47 | +188.18% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $27.45 | +218.76% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.66 | +683.13% | 3 | Feb 9, 2021 |
Alto Neuroscience
Apr 22, 2026
Maintains: Buy
Price Target: $30
Current: $24.52
Upside: +22.35%
ProQR Therapeutics
Apr 9, 2026
Maintains: Buy
Price Target: $4
Current: $1.55
Upside: +158.06%
iBio, Inc.
Apr 9, 2026
Maintains: Buy
Price Target: $5
Current: $1.68
Upside: +197.62%
Monopar Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $100
Current: $53.20
Upside: +87.97%
Alnylam Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $425
Current: $305.54
Upside: +39.10%
Stoke Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $35
Current: $34.03
Upside: +2.85%
Coya Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $14
Current: $4.32
Upside: +224.07%
Orchestra BioMed Holdings
Mar 12, 2026
Maintains: Buy
Price Target: $20
Current: $4.13
Upside: +384.26%
SAB Biotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $3.52
Upside: +297.73%
Dyne Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $38
Current: $18.26
Upside: +108.11%
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $12.89
Upside: +16.37%
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $73.91
Upside: +8.24%
Jan 5, 2026
Maintains: Buy
Price Target: $40
Current: $0.90
Upside: +4,342.47%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.20
Upside: +19.05%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $7.70
Upside: +354.55%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $8.10
Upside: -25.93%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.97
Upside: +204.57%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.41
Upside: +1,865.60%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $15.52
Upside: -61.34%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $1.11
Upside: +34,134.23%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.03
Upside: +584.93%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $3.47
Upside: +188.18%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $27.45
Upside: +218.76%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.66
Upside: +683.13%